Phase I Radioimmunotherapy Trial with Iodine-131—Labeled Humanized MN-14 Anti—Carcinoembryonic Antigen Monoclonal Antibody in Patients with Metastatic Gastrointestinal and Colorectal Cancer

Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins

“…24,[24][25][26][27][28][29][30][31] We show here that MN-14 binds an epitope in region III (A3B3) of the CEA molecule, consistent with its designation as a Class III anti-CEAspecific monoclonal antibody. 22 In this study, we constructed a CEA-Fc fusion protein that consists of the same A3B3 region of CEA and the Fc region of IgG1.…”

Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma

“…hMN-14 is a humanized mAb targeting carcinoembryonic antigen (28) and a phase II radioimmunotherapy trial using 131 I-hMN-14 has been recently reported (29). A dose of 60 mCi/m 2 was studied in 30 patients with small volume metastatic colorectal cancer.…”

Combined 90Yttrium‐DOTA‐labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft

“…One potential means for overcoming this problem is the use of radiolabeled antibodies that are able to target metastatic as well as primary tumor sites with minimal reactivity to normal tissues. Radiolabeled antibodies have been used with some success in numerous cancers, such as metastatic colorectal cancer [13][14][15][16] and several forms of hematologic malignancy. [17][18][19][20][21][22][23] Although mechanistically complex, the inherent radiosensitivity of many hematologic malignancies, as well as the biological activity of the antibodies employed, have drawn considerable attention to radioimmunotherapy as a potential front-line therapeutic procedure.…”